System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Epublish

PubMed: 42516861 DOI: 10.1016/j.jscai.2026.105315

Paclitaxel-Coated Balloons Versus Sirolimus-Coated Balloons for Coronary Artery Lesions: A Nationwide Cohort Study From SCAAR.

J Soc Cardiovasc Angiogr Interv 5(6):105315

Authors: Sacharias von Koch, Troels Yndigegn, Sasha Koul, Sammy Zwackman, Liyew Desta, Oskar Angerås, Elmir Omerovic, Felix Böhm, Ole Fröbert, Per Grimfjärd, Stefan James, David Erlinge, Moman A Mohammad

Affiliations

  • Division of Cardiology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
  • Department of Cardiology, Skåne University Hospital, Lund, Sweden.
  • Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.
  • Department of Cardiology, Linköping University, Linköping, Sweden.
  • Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
  • Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.
  • Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Department of Clinical Sciences, Danderyd University Hospital, Karolinska Institutet, Stockholm, Sweden.
  • Department of Clinical Medicine, Aarhus University, Denmark.
  • Department of Cardiology, Faculty of Health, Örebro University, Sweden.
  • Department of Internal Medicine, Västmanlands Hospital, Västerås, Sweden.
  • Department of Medical Sciences and Cardiology, Uppsala University and Uppsala Clinical Research Center, Sweden.

Abstract

BACKGROUND

Sirolimus-coated balloons (SCB) are a potential alternative to paclitaxel-coated balloons (PCB) in the context of percutaneous coronary intervention (PCI). However, comparative data between SCB and PCB remain limited. We aimed to compare the outcome of PCI with contemporary PCB or SCB in a real-world clinical setting.

METHODS

The Swedish Coronary Angiography and Angioplasty Registry (SCAAR) was used to include all patients undergoing PCI with PCB or SCB between January 1, 2022 and May 16, 2025. The primary outcome was target segment revascularization assessed on coronary artery segment level. Outcome was assessed using multivariable-adjusted Cox regression.

RESULTS

A total of 7855 PCB-treated and 502 SCB-treated segments were included. PCB was less frequently used for in-stent restenosis (28.0% vs 34.3%). After a 1-year follow-up period, no difference was observed between PCB and SCB in terms of target segment revascularization (3.3% vs 5.8%; hazard ratio [HR], 1.37; 95% CI, 0.83-2.25), target vessel revascularization (5.2% vs 8.1%; HR, 1.24; 95% CI, 0.78-1.97), restenosis (2.8% vs 4.4%; HR, 1.44; 95% CI, 0.85-2.44), myocardial infarction (3.1% vs 4.9%; HR, 0.74; 95% CI, 0.41-1.32), repeat PCI (8.8% vs 10.8%; HR, 1.04; 95% CI, 0.72-1.51), or all-cause mortality (4.4% vs 3.2%; HR, 1.37; 95% CI, 0.34-1.15).

CONCLUSIONS

In this study investigating outcome after PCI with drug-coated balloons, no statistically significant differences in 1-year clinical outcomes were observed between PCB and SCB.

MeSH

Paclitaxel, Percutaneous Coronary Intervention, Cohort Studies, Sirolimus, Arteries, Wounds And Injuries